Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

To: CPark who wrote (56125)

5/3/2020 1:51:03 PM

From: weatherproof

10 Recommendations of 63284

>>HR+/HER2- BC is shaping up to be the biggest catalyst/question mark in the minds of Wall St. analysts. I’ve heard that Trop-2 is expressed differently than in mTNBC, thus leading to questions about ASCENT trial read through to TROPICS-02.<<
We're seeing similar results for Trodelvy for HR+/HER- relative to mTNBC. The trial design for TROPICS-02 is very interesting. As with the mTNBC ph III ASCENT trial, the primary endpoint in TROPICS-02 is PFS. However, this trial allows for an interim analysis whereby ORR will be looked at and may form the basis of an application for accelerated approval. I don't know how many patients have been enrolled prior to the the halt due to COVID-19, but it would be interesting to know how close we are to getting enough data on ORR for the purpose of applying for AA.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next